{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:58:47Z","timestamp":1761818327397,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jgo.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T21:40:35Z","timestamp":1635284435000},"page":"302-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study"],"prefix":"10.1016","volume":"13","author":[{"given":"Gerardo","family":"Rosati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Corsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Brugnatelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Dell'Aquila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Cinausero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Rapisardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Reggiardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Bilancia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jgo.2021.10.007_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jgo.2021.10.007_bb0010","first-page":"184","article-title":"Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone","volume":"7","author":"Freeman","year":"2008","journal-title":"Clin Colorectal Cancer"},{"issue":"14","key":"10.1016\/j.jgo.2021.10.007_bb0015","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jgo.2021.10.007_bb0020","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jgo.2021.10.007_bb0025","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.jgo.2021.10.007_bb0030","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2021.10.007_bb0035","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jgo.2016.01.006","article-title":"A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer","volume":"7","author":"Rosati","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2021.10.007_bb0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40266-017-0439-9","article-title":"Targeted therapies in elderly patients with metastatic colorectal cancer: a review of the evidence","volume":"34","author":"Tapia Rico","year":"2017","journal-title":"Drugs Aging"},{"issue":"10","key":"10.1016\/j.jgo.2021.10.007_bb0045","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"Bokemeyer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2021.10.007_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/gutjnl-2015-310912","article-title":"Global patterns and trends in colorectal cancer incidence and mortality","volume":"66","author":"Arnold","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jgo.2021.10.007_bb0055","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/annonc\/mdu253","article-title":"Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013","volume":"26","author":"Papamichael","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2021.10.007_bb0060","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2021.10.007_bb0065","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chron Dis"},{"issue":"8","key":"10.1016\/j.jgo.2021.10.007_bb0070","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2021.10.007_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2021.10.007_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdu210","article-title":"Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations","volume":"26","author":"Decoster","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2021.10.007_bb0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S2468-1253(19)30041-X","article-title":"Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial","volume":"4","author":"Winther","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jgo.2021.10.007_bb0090","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000445365","article-title":"A questionnaire study to assess the value of the vulnerable elders survey, G8, and predictors of toxicity as screening tools for frailty and toxicity in geriatric cancer patients","volume":"39","author":"Hentschel","year":"2016","journal-title":"Oncol Res Treat"},{"issue":"22","key":"10.1016\/j.jgo.2021.10.007_bb0095","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell\u2019Italia Meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2021.10.007_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12885-021-07823-7","article-title":"Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis","volume":"21","author":"Kawai","year":"2021","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2021.10.007_bb0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol"},{"year":"2020","series-title":"Toxicity and Efficacy of 1st Line Cetuximab (Cetux)-Based Therapy in RAS Wildtype (WT) Older Patients (pts) with Metastatic Colorectal Cancer (mCRC): A Pooled Analysis from 1,274 pts in the ARCAD Database","author":"Papamichael","key":"10.1016\/j.jgo.2021.10.007_bb0110"},{"year":"2010","series-title":"Cetuximab and 1st-Line Chemotherapy in Elderly and Younger Patients with Metastatic Colorectal Cancer (MCRC): A Pooled Analysis of the CRYSTAL and OPUS Studies","author":"Folprecht","key":"10.1016\/j.jgo.2021.10.007_bb0115"},{"issue":"6","key":"10.1016\/j.jgo.2021.10.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000086","article-title":"Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial","volume":"1","author":"Martinelli","year":"2017","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.jgo.2021.10.007_bb0125","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1634\/theoncologist.2011-0406","article-title":"First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study","volume":"17","author":"Sastre","year":"2012","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.jgo.2021.10.007_bb0130","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jgo.2020.06.003","article-title":"First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study","volume":"11","author":"M\u00e9ndez M\u00e9ndez","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2021.10.007_bb0135","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jgo.2018.11.011","article-title":"Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41\/10","volume":"10","author":"Kienle","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2021.10.007_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/annonc\/mdv491","article-title":"Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)","volume":"27","author":"Aparicio","year":"2016","journal-title":"Ann Oncol"},{"issue":"9779","key":"10.1016\/j.jgo.2021.10.007_bb0145","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"year":"2014","series-title":"Impact of Baseline Age on Efficacy and Safety of First-Line Panitumumab (PMAB) + FOLFOX4 vs FOLFOX4 Treatment","author":"Douillard","key":"10.1016\/j.jgo.2021.10.007_bb0150"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821002393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406821002393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:54:52Z","timestamp":1761818092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406821002393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1879406821002393"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2021.10.007","relation":{},"ISSN":["1879-4068"],"issn-type":[{"type":"print","value":"1879-4068"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}